CINQAIR is an
interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on
maintenance treatment of patients with severe asthma aged 18 years and older,
and with an eosinophilic phenotype.
Limitations of Use: CINQAIR is not indicated for:
Please
see full
Prescribing Information.
DOSAGE AND ADMINISTRATION
·
CINQAIR is for
intravenous infusion only. Do not administer as an intravenous push or bolus
·
CINQAIR should be
administered in a healthcare setting by a healthcare professional prepared to
manage anaphylaxis
·
Recommended dosage
regimen is 3 mg/kg once every 4 weeks by intravenous infusion over 20-50
minutes
DOSAGE FORMS AND STRENGTHS
Injection: 100 mg/10 mL (10 mg/mL) solution in
single-use vials
Please see full Prescribing Information.
Teva Support Solutions® is a registered trademark of Teva Pharmaceutical Industries Ltd.
©2021 Teva Respiratory, LLC. CIQ-41297 03/21
Please see
accompanying Full Prescribing Information, including Boxed WARNING.
INDICATION AND IMPORTANT SAFETY INFORMATION
CINQAIR is an
interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on
maintenance treatment of patients with severe asthma aged 18 years and older,
and with an eosinophilic phenotype.
Limitations
of Use: CINQAIR is not indicated for:
Important Safety Information
WARNING:
ANAPHYLAXIS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Please see
accompanying Full
Prescribing Information, including Boxed WARNING.